FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295128346> ?p ?o ?g. }

• W4295128346 endingPage "1129" @default.
• W4295128346 startingPage "1117" @default.
• W4295128346 abstract "The IMMUNED trial previously showed significant improvements in recurrence-free survival for adjuvant nivolumab plus ipilimumab as well as for adjuvant nivolumab alone in patients with stage IV melanoma with no evidence of disease after resection or radiotherapy. Here, we report the final analysis, including overall survival data.IMMUNED was an investigator-sponsored, double-blind, placebo-controlled, three-arm, phase 2 trial conducted in 20 academic medical centres in Germany. Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy. Patients were randomly assigned (1:1:1) to either nivolumab plus ipilimumab (nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab 3 mg/kg every 2 weeks), nivolumab monotherapy (nivolumab 3 mg/kg every 2 weeks), or matching placebo, for up to 1 year. The primary endpoint was recurrence-free survival in the intention-to-treat population. Secondary endpoints were time-to-recurrence, overall survival, progression-free survival or recurrence-free survival 2 (in patients in the placebo group who crossed over to nivolumab monotherapy after experiencing disease recurrence), and safety endpoints. This trial is registered on ClinicalTrials.gov (NCT02523313), and is complete.Between Sept 2, 2015, and Nov 20, 2018, 175 patients were enrolled in the study, and 167 were randomly assigned to receive either nivolumab plus ipilimumab (n=56), nivolumab plus ipilimumab-matching placebo (n=59), or double placebo control (n=52). At a median follow-up of 49·2 months (IQR 34·9-58·1), 4-year recurrence-free survival was 64·2% (95% CI 49·2-75·9) in the nivolumab plus ipilimumab group, 31·4% (19·7-43·8) in the nivolumab alone group, and 15·0% (6·7-26·6) in the placebo group. The hazard ratio (HR) for recurrence for the nivolumab plus ipilimumab group versus placebo was 0·25 (97·5% CI 0·13-0·48; p<0·0001), and for the nivolumab group versus placebo was 0·60 (0·36-1·00; p=0·024). Median overall survival was not reached in any treatment group. The HR for overall survival was significantly in favour of the nivolumab plus ipilimumab group versus placebo (HR 0·41; 95% CI 0·17-0·99; p=0·040), but not for the nivolumab group versus placebo (HR 0·75; 0·36-1·56; p=0·44). 4-year overall survival was 83·8% (95% CI 68·8-91·9) in the nivolumab plus ipilimumab group, 72·6% (57·4-83·2) in the nivolumab alone group, and 63·1% (46·9-75·6) in the placebo group. The median progression-free survival or recurrence-free survival 2 of patients in the placebo group who crossed over to nivolumab monotherapy after experiencing disease recurrence was not reached (95% CI 21·2 months to not reached). Rates of grade 3-4 treatment-related adverse events remained largely unchanged compared with our previous report, occurring in 71% (95% CI 57-82) of the nivolumab plus ipilimumab group, and 29% (95% CI 17-42) of patients receiving nivolumab alone. There were no treatment-related deaths.Both active regimens continued to show significantly improved recurrence-free survival compared with placebo in patients with stage IV melanoma with no evidence of disease who were at high risk of recurrence. Overall survival was significantly improved for patients receiving nivolumab plus ipilimumab compared with placebo. Use of subsequent anti-PD-1-based therapy was high in patients in the placebo group after recurrence and most likely impacted the overall survival comparison of nivolumab alone versus placebo. The recurrence-free and overall survival benefit of nivolumab plus ipilimumab over placebo reinforces the change of practice already initiated for the treatment of patients with stage IV melanoma with no evidence of disease.Bristol-Myers Squibb." @default.
• W4295128346 created "2022-09-11" @default.
• W4295128346 creator A5001548963 @default.
• W4295128346 creator A5004458225 @default.
• W4295128346 creator A5004684398 @default.
• W4295128346 creator A5007887862 @default.
• W4295128346 creator A5008750058 @default.
• W4295128346 creator A5013410369 @default.
• W4295128346 creator A5014480763 @default.
• W4295128346 creator A5015081105 @default.
• W4295128346 creator A5017172335 @default.
• W4295128346 creator A5025256131 @default.
• W4295128346 creator A5026540360 @default.
• W4295128346 creator A5034365278 @default.
• W4295128346 creator A5037516725 @default.
• W4295128346 creator A5041633337 @default.
• W4295128346 creator A5042724544 @default.
• W4295128346 creator A5044736874 @default.
• W4295128346 creator A5049229784 @default.
• W4295128346 creator A5052208505 @default.
• W4295128346 creator A5056213766 @default.
• W4295128346 creator A5056227404 @default.
• W4295128346 creator A5056685282 @default.
• W4295128346 creator A5064923908 @default.
• W4295128346 creator A5066170899 @default.
• W4295128346 creator A5067045121 @default.
• W4295128346 creator A5067776208 @default.
• W4295128346 creator A5071942259 @default.
• W4295128346 creator A5077331259 @default.
• W4295128346 creator A5082974165 @default.
• W4295128346 creator A5084326743 @default.
• W4295128346 creator A5087671839 @default.
• W4295128346 creator A5088963317 @default.
• W4295128346 creator A5090351890 @default.
• W4295128346 date "2022-10-01" @default.
• W4295128346 modified "2023-10-14" @default.
• W4295128346 title "Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial" @default.
• W4295128346 cites W2070825440 @default.
• W4295128346 cites W2328012298 @default.
• W4295128346 cites W2752210999 @default.
• W4295128346 cites W2752227448 @default.
• W4295128346 cites W2797309423 @default.
• W4295128346 cites W2902435965 @default.
• W4295128346 cites W2964599082 @default.
• W4295128346 cites W3024460671 @default.
• W4295128346 cites W3043703771 @default.
• W4295128346 cites W3081051636 @default.
• W4295128346 cites W3082456432 @default.
• W4295128346 cites W3087697977 @default.
• W4295128346 cites W3127822472 @default.
• W4295128346 cites W3153228158 @default.
• W4295128346 cites W3158422249 @default.
• W4295128346 cites W4200583820 @default.
• W4295128346 cites W4226258201 @default.
• W4295128346 cites W4281783912 @default.
• W4295128346 doi "https://doi.org/10.1016/s0140-6736(22)01654-3" @default.
• W4295128346 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36099927" @default.
• W4295128346 hasPublicationYear "2022" @default.
• W4295128346 type Work @default.
• W4295128346 citedByCount "26" @default.
• W4295128346 countsByYear W42951283462022 @default.
• W4295128346 countsByYear W42951283462023 @default.
• W4295128346 crossrefType "journal-article" @default.
• W4295128346 hasAuthorship W4295128346A5001548963 @default.
• W4295128346 hasAuthorship W4295128346A5004458225 @default.
• W4295128346 hasAuthorship W4295128346A5004684398 @default.
• W4295128346 hasAuthorship W4295128346A5007887862 @default.
• W4295128346 hasAuthorship W4295128346A5008750058 @default.
• W4295128346 hasAuthorship W4295128346A5013410369 @default.
• W4295128346 hasAuthorship W4295128346A5014480763 @default.
• W4295128346 hasAuthorship W4295128346A5015081105 @default.
• W4295128346 hasAuthorship W4295128346A5017172335 @default.
• W4295128346 hasAuthorship W4295128346A5025256131 @default.
• W4295128346 hasAuthorship W4295128346A5026540360 @default.
• W4295128346 hasAuthorship W4295128346A5034365278 @default.
• W4295128346 hasAuthorship W4295128346A5037516725 @default.
• W4295128346 hasAuthorship W4295128346A5041633337 @default.
• W4295128346 hasAuthorship W4295128346A5042724544 @default.
• W4295128346 hasAuthorship W4295128346A5044736874 @default.
• W4295128346 hasAuthorship W4295128346A5049229784 @default.
• W4295128346 hasAuthorship W4295128346A5052208505 @default.
• W4295128346 hasAuthorship W4295128346A5056213766 @default.
• W4295128346 hasAuthorship W4295128346A5056227404 @default.
• W4295128346 hasAuthorship W4295128346A5056685282 @default.
• W4295128346 hasAuthorship W4295128346A5064923908 @default.
• W4295128346 hasAuthorship W4295128346A5066170899 @default.
• W4295128346 hasAuthorship W4295128346A5067045121 @default.
• W4295128346 hasAuthorship W4295128346A5067776208 @default.
• W4295128346 hasAuthorship W4295128346A5071942259 @default.
• W4295128346 hasAuthorship W4295128346A5077331259 @default.
• W4295128346 hasAuthorship W4295128346A5082974165 @default.
• W4295128346 hasAuthorship W4295128346A5084326743 @default.
• W4295128346 hasAuthorship W4295128346A5087671839 @default.
• W4295128346 hasAuthorship W4295128346A5088963317 @default.
• W4295128346 hasAuthorship W4295128346A5090351890 @default.
• W4295128346 hasConcept C121608353 @default.
• W4295128346 hasConcept C126322002 @default.
• W4295128346 hasConcept C141071460 @default.

• next